A systematic review of the psychiatric side-effects of efavirenz.
about
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEfavirenz and the CNS: what we already know and questions that need to be answeredAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data.Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.Reporting of drug induced depression and fatal and non-fatal suicidal behaviour in the UK from 1998 to 2011.Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.When to start antiretroviral therapy: the need for an evidence base during early HIV infectionAntiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort studyCase report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Prevalence and correlates of probable common mental disorders in a population with high prevalence of HIV in ZimbabweSingle Tablet Regimen Usage and Efficacy in the Treatment of HIV Infection in AustraliaTolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsSafety of varenicline among smokers enrolled in the lung HIV study.Sleep disturbances in persons living with HIVPharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.AIDS treatment and mental health: evidence from Uganda.Untreated HIV infection is associated with higher blood alcohol levels.Evaluating sleep and cognition in HIVPsychiatric Symptoms in Patients Receiving Dolutegravir.Neuronal toxicity of efavirenz: a systematic review.The relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care.A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.A 33-year-old patient with human immunodeficiency virus on antiretroviral therapy with efavirenz-induced complex partial seizures: a case report.Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.[Poor quality of sleep associated with low adherence to highly active antiretroviral therapy in Peruvian patients with HIV/AIDS].Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia.Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania.Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.Brief Behavioral Treatment for Insomnia in Persons Living with HIV.Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events.Fatigue Symptom Management in People Living With Human Immunodeficiency Virus.Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.Would a CYP2B6 test help HIV patients being treated with efavirenz?Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape.Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 t
P2860
Q28081266-F7832653-1D05-414C-8F6C-61B516F64645Q28085028-6858E691-E3F2-47E7-AD80-DF3CA45BAEDDQ30834094-CB6D0DDB-7EFB-42BB-886C-CD1BC0E1BADAQ31040458-25FDEFCC-B25C-4E98-97A7-81C73227E60EQ33910378-58D86320-521F-4B52-8D0C-0C45414EF834Q34285010-F54A8B7E-20A9-4FEE-8EEA-E1376AD73334Q34310827-E8B06660-E506-40C3-BB6D-7C8346161EB2Q34756398-752F96AD-9159-425F-BE2B-67CC86D172ACQ34773308-E497431F-595F-43DF-8029-9E2DED87CE49Q35547048-59119E90-285F-4202-A6F2-D9AE43C92F33Q35794099-086E3CCF-890B-40E1-954A-BF221891A86DQ35910664-26F93E21-3FC2-43D2-8D96-1D2CA3178313Q35939679-913A8B3D-24CC-4835-B1E9-0A13DFDB08B8Q36208913-13AA2E74-9B5B-407F-B75B-E31DDD6002A9Q36266624-FAFED9DD-FC4D-43F2-A1F5-9570E456B824Q36437792-2D247EF3-6F67-4039-AFA7-B365AA9C00F0Q36471990-FB06C90A-3DC5-4D9C-80C2-728586C9ECB4Q36528391-297CF8AE-F036-49D8-BCCB-1D171875387CQ36554279-DCFEEA9E-406D-44C1-BEA7-CB9C32016EE2Q37019475-137EE8BE-D31C-4720-85EA-08C15F184924Q37045314-AFD1A6DF-0321-45D4-BF3A-44A922505932Q37294737-1A31C1C3-1DFC-4F1C-B5A9-E9050DE14003Q37659135-091D5D43-A753-4AC0-9F76-5DA61E5C4F7EQ38124394-E8FF8933-5258-446F-B9E9-EAE92A42B95DQ38657643-35E49162-CEF2-4872-A25D-9091C45A0003Q38743628-BE876BF0-76B4-4FF9-AC55-FDA1E47AB627Q40117598-EEC4C66B-1FB3-4B7D-A351-9529C52AFCB2Q40223622-6809F65E-FAB9-4609-B44F-276803E2149DQ41155611-6054989A-A72D-4EF2-A9D7-CDFF32394EF7Q41208022-99F7B2E1-B5C3-4289-96CA-BB2A43699884Q42011164-040947FC-8DB4-40A7-AD28-B0F2568509B9Q47567926-1D6D3FCE-4E6A-4FBB-931E-FC75108D36FDQ47718267-6839A3A2-6134-4E30-92A7-330A486A5D60Q47841376-9972B0FC-2D30-492F-A294-6DB7125601A0Q48142521-7802D511-2E4E-40A4-8BEE-5247FF1F1D35Q49336678-3A51DEFF-58BB-496C-9115-2F19CDDB0970Q50051675-EC748599-350F-4CE2-9F36-677A17C69273Q50849720-E2347AEB-A302-465D-B1A1-663D1B725719Q53759304-7E9C90A8-E104-43F9-9142-61C638FC98F8Q58254289-C96EAA27-3663-4A07-AA95-73727C23A820
P2860
A systematic review of the psychiatric side-effects of efavirenz.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A systematic review of the psychiatric side-effects of efavirenz.
@en
A systematic review of the psychiatric side-effects of efavirenz.
@nl
type
label
A systematic review of the psychiatric side-effects of efavirenz.
@en
A systematic review of the psychiatric side-effects of efavirenz.
@nl
prefLabel
A systematic review of the psychiatric side-effects of efavirenz.
@en
A systematic review of the psychiatric side-effects of efavirenz.
@nl
P2860
P1433
P1476
A systematic review of the psychiatric side-effects of efavirenz.
@en
P2093
Christopher A Kenedi
Harold W Goforth
P2860
P2888
P304
P356
10.1007/S10461-011-9939-5
P577
2011-11-01T00:00:00Z